Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This case report describes a male cat with demodicosis primarily attributed to Demodex cati, suggesting the generalized disease may have been exacerbated by pruritus related to flea infestation.

The document explains various skin conditions in cats and how to diagnose and treat them.

The document concludes that various disorders can cause hair loss in dogs, each requiring different treatments, and some may heal on their own.

This article discusses the pervasive presence and influence of advertisements in daily life but does not provide new research findings.

In this study, tebentafusp-tebn improved overall survival in patients with metastatic uveal melanoma compared to standard therapies, despite higher rates of significant adverse events.

The BAYONET trial is a phase II study designed to assess the efficacy and safety of combining encorafenib, binimetinib, and cetuximab for patients with BRAF V600E-mutant metastatic colorectal cancer that is resistant to encorafenib plus cetuximab; results are not yet reported.

This review highlights the promising clinical outcomes of sacituzumab tirumotecan (sac-TMT), an antibody-drug conjugate for breast cancer that targets TROP2, demonstrating improved response rates and progression-free survival, with manageable safety concerns including primarily mild-to-moderate nausea and alopecia.

In this phase 3 trial, baricitinib showed effectiveness and safety in both adolescents and adults with severe alopecia areata, with adolescents achieving higher response rates despite more severe baseline conditions, suggesting the advantages of early treatment.

This study suggests that combining bendamustine with tucidinostat may improve survival in patients with relapsed or refractory adult T-cell leukemia/lymphoma, highlighting its potential for clinical investigation.

In this study, two patients with severe alopecia areata who did not respond well to oral tofacitinib showed more than 50% hair regrowth after a single dose of intramuscular triamcinolone acetonide.

Terbinafine is more effective than itraconazole for toenail fungus, especially in older patients, and debridement improves its effectiveness.

This study found that among Japanese IBD patients, the NUDT15 p.Arg139Cys variant was significantly associated with thiopurine-induced leukopenia and severe hair loss, suggesting its genotyping is important for predicting these adverse events.

In this study, two patients with refractory juvenile dermatomyositis improved clinically and in disease activity after receiving the JAK inhibitor tofacitinib, showing potential effects in managing the condition.

In this study, researchers developed a dissolvable microneedle patch containing baricitinib for alopecia areata treatment, reporting significantly higher hair growth in mouse models compared to controls, suggesting its potential as an effective, pain-free topical therapy.

This study found that dabrafenib was well tolerated and led to durable responses in patients with BRAF-mutant differentiated thyroid carcinoma, with a median progression-free survival of 11.3 months.

Tavaborole is a safe and effective toenail fungus treatment, with the 5% solution being the best option.

This study reports that sacituzumab govitecan achieved a 33.3% overall response rate in patients with metastatic triple-negative breast cancer who had prior treatments, with a median response duration of 7.7 months.

In this study, Typhonium flagelliforme leaf-ethanolic extract combined with natural interferon was observed to stabilize body weight, inhibit tumor growth, and reduce mitosis, angiogenesis, and certain protein expressions in carcinogen-induced tumors in female mice, suggesting potential antitumor effects.

This source reports that based on international Phase 3 trial results, the JAK1/2 inhibitor baricitinib was approved in Japan in June 2022 for treating extensive alopecia areata, offering a potentially useful treatment option.

This study found that oral baricitinib was more effective than methotrexate in treating severe alopecia areata, with significant improvements in SALT scores over six months.

In this study, baricitinib treatment over an average of 18.5 months resulted in a 72% reduction in alopecia severity scores among patients aged 65 or older, with mild adverse effects and no severe complications reported.

This study found that a microneedle patch containing tofacitinib-loaded nanoparticles significantly increased hair follicle numbers and promoted hair regeneration with less drug compared to daily topical tofacitinib, suggesting it may be an effective strategy for alopecia treatment by reducing dosing frequency and enhancing drug delivery.

This case report found that a 48-year-old woman with idiopathic twenty-nail dystrophy experienced significant improvement in nail appearance after six months of treatment with oral Upadacitinib.

This study evaluated the real-world safety of Tepotinib for treating NSCLC with METex14 skipping mutations, confirming known adverse events and identifying new signals like deafness and taste disorder, especially highlighting early monitoring.

In this case report, a 42-year-old woman with cutaneous dermatomyositis showed significant improvement, including reduction of erythema, pruritus, and scaling, after starting JAK inhibitor tofacitinib, especially when conventional systemic treatments failed and intravenous immune globulin wasn't viable.

In this randomized controlled trial, researchers found that after six months of treatment, oral baricitinib was significantly more effective than methotrexate for improving hair regrowth in patients with severe alopecia areata, as measured by the Severity of Alopecia Tool score.

In this study on mice, a baricitinib-loaded microneedle patch enhanced hair growth in alopecia areata lesions (68% vs control: 33%, p < 0.05), suggesting it may deliver treatment effectively and pain-free, with fewer systemic side effects.

This study reports that baricitinib was more effective than placebo in promoting hair growth in adults with severe alopecia areata after 36 weeks of treatment in clinical trials.